Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin

被引：7

作者：

Bistervels, Ingrid M. ^{[1
,2
]}

Bavalia, Roisin ^{[1
]}

Beyer-Westendorf, Jan ^{[3
]}

ten Cate-Hoek, Arina J. ^{[4
]}

Schellong, Sebastian M. ^{[5
]}

Kovacs, Michael J. ^{[6
]}

Falvo, Nicolas ^{[7
]}

Meijer, Karina ^{[8
]}

Stephan, Dominique ^{[9
]}

Boersma, Wim G. ^{[10
]}

ten Wolde, Marije ^{[2
]}

Couturaud, Francis ^{[11
]}

Verhamme, Peter ^{[12
]}

Brisot, Dominique ^{[13
]}

Kahn, Susan R. ^{[14
]}

Ghanima, Waleed ^{[15
,16
]}

Montaclair, Karine ^{[17
]}

Hugman, Amanda ^{[18
]}

Carroll, Patrick ^{[19
]}

Pernod, Gilles ^{[20
]}

Sanchez, Olivier ^{[21
]}

Ferrari, Emile ^{[22
]}

Roy, Pierre-Marie ^{[23
]}

Sevestre-Pietri, Marie-Antoinette ^{[24
]}

Birocchi, Simone ^{[25
]}

Wik, Hilde S. ^{[26
]}

Hutten, Barbara A. ^{[27
]}

Coppens, Michiel ^{[1
]}

Naue, Christiane ^{[3
]}

Grosso, Michael A. ^{[28
]}

Shi, Minggao ^{[28
]}

Lin, Yong ^{[28
]}

Quere, Isabelle ^{[29
]}

Middeldorp, Saskia ^{[1
,30
,31
]}

机构：

[1] Univ Amsterdam, Dept Vasc Med, Amsterdam UMC, Amsterdam Cardiovasc Sci, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands

[2] Flevo Hosp, Dept Internal Med, Almere, Netherlands

[3] Univ Hosp Carl Gustav Carus Dresden, Dept Med 1, Div Hematol & Hemostasis, Thrombosis Res, Dresden, Germany

[4] Maastricht Univ Med Ctr, Thrombosis Expertise Ctr, Heart Vasc Ctr, Maastricht, Netherlands

[5] Stadt Klinikum Dresden, Med Klin, Dresden, Germany

[6] Victoria Hosp, London Hlth Sci Ctr, Dept Hematol & Thrombosis, London, ON, Canada

[7] CHU Dijon, Dept Internal Med & Immunol, Dijon, France

[8] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[9] Reg Univ Hosp, Dept Hypertens Vasc Dis & Clin Pharmacol, Strasbourg, France

[10] Noordwest Ziekenhuisgrp, Dept Pulmonol, Alkmaar, Netherlands

[11] Ctr Hosp Reg Univ Brest, Dept Pulmonol, Brest, France

[12] Univ Hosp Leuven, Dept Vasc Med & Hemostasis, Leuven, Belgium

[13] Clin Parc, Dept Vasc Med, Castelnau Le Lez, France

[14] McGill Univ, Dept Med, Montreal, PQ, Canada

[15] Univ Oslo, Dept Res, Ostfold Hosp, Oslo, Norway

[16] Univ Oslo, Inst Clin Med, Oslo, Norway

[17] Ctr Hosp Le Mans, Dept Cardiol, Le Mans, France

[18] St George Hosp, Dept Haematol, Sydney, NSW, Australia

[19] Redcliffe Hosp, Dept Vasc Med, Woolloongabba, Qld, Australia

[20] Ctr Hosp Reg Univ Grenoble Alpes, Dept Med, Grenoble, France

[21] Hop Europeen Georges Pompidou, Dept Pulmonol, Paris, France

[22] Ctr Hosp Univ Nice, Dept Cardiol, Nice, France

[23] Centre Hosp Univ, Dept Emergency Med, Angers, France

[24] Ctr Hosp Reg Univ Amiens, Dept Med, Amiens, France

[25] SanPaolo Hosp, Dept Hematol & Thrombosis, Milan, Italy

[26] Oslo Univ Hosp, Dept Haematol, Oslo, Norway

[27] Univ Amsterdam, Dept Epidemiol & Data Sci, Amsterdam UMC, Amsterdam Cardiovasc Sci, Amsterdam, Netherlands

[28] Daiichi Sankyo Pharma Dev, Basking Ridge, NJ USA

[29] Montpellier Univ, InnoVTE Network, CHU Montpellier, Dept Vasc Med,IDESP Inserm, Montpellier, France

[30] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands

[31] Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci RIHS, Nijmegen, Netherlands

来源：

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS | 2022年 / 6卷 / 05期

关键词：

edoxaban; postthrombotic syndrome; quality of life; venous thrombosis; warfarin; CATHETER-DIRECTED THROMBOLYSIS; COMPRESSION STOCKINGS; VENOUS THROMBOSIS; QOL/SYM QUESTIONNAIRE; K ANTAGONISTS; RIVAROXABAN; PREVENTION; THROMBOEMBOLISM; COMPLICATIONS; SF-36;

D O I：

10.1002/rth2.12748

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Postthrombotic syndrome (PTS) is a long-term complication after deep vein thrombosis (DVT) and can affect quality of life (QoL). Pathogenesis is not fully understood but inadequate anticoagulant therapy with vitamin K antagonists is a known risk factor for the development of PTS. Objectives To compare the prevalence of PTS after acute DVT and the long-term QoL following DVT between patients treated with edoxaban or warfarin. Methods We performed a long-term follow-up study in a subset of patients with DVT who participated in the Hokusai-VTE trial between 2010 and 2012 (NCT00986154). Primary outcome was the prevalence of PTS, defined by the Villalta score. The secondary outcome was QoL, assessed by validated disease-specific (VEINES-QOL) and generic health-related (SF-36) questionnaires. Results Between 2017 and 2020, 316 patients were enrolled in 26 centers in eight countries, of which 168 (53%) patients had been assigned to edoxaban and 148 (47%) to warfarin during the Hokusai-VTE trial. Clinical, demographic, and thrombus-specific characteristics were comparable for both groups. Mean (SD) time since randomization in the Hokusai-VTE trial was 7.0 (1.0) years. PTS was diagnosed in 85 (51%) patients treated with edoxaban and 62 (42%) patients treated with warfarin (adjusted odds ratio 1.6, 95% CI 1.0-2.6). Mean differences in QoL scores between treatment groups were not clinically relevant. Conclusion Contrary to our hypothesis, the prevalence of PTS tended to be higher in patients treated with edoxaban compared with warfarin. No differences in QoL were observed. Further research is warranted to unravel the role of anticoagulant therapy on development of PTS.

引用

页数：13

共 50 条

[1] Compression therapy for prevention of post-thrombotic syndrome [J].

Appelen, Diebrecht ;

van Loo, Eva ;

Prins, Martin H. ;

Neumann, Martino H. A. M. ;

Kolbach, Dinanda N. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (09)

[2] Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin [J].

Bavalia, Roisin ;

Bistervels, Ingrid M. ;

Boersma, Wim G. ;

Quere, Isabelle ;

Brisot, Dominique ;

Falvo, Nicolas ;

Stephan, Dominique ;

Couturaud, Francis ;

Schellong, Sebastian ;

Montaclair, Karine ;

Ghanima, Waleed ;

ten Wolde, Marije ;

Coppens, Michiel ;

Ferrari, Emile ;

Sanchez, Olivier ;

Carroll, Patrick ;

Kahn, Susan R. ;

Meijer, Karina ;

Birocchi, Simone ;

Kovacs, Michael J. ;

Hugman, Amanda ;

ten Cate, Hugo ;

Wik, Hilde ;

Pernod, Gilles ;

Grosso, Michael A. ;

Shi, Minggao ;

Lin, Yong ;

Hutten, Barbara A. ;

Verhamme, Peter ;

Middeldorp, Saskia ;

Beyer-Westendorf, Jan ;

Roy, Pierre-Marie ;

Sevestre-Pietri, Marie-Antoinette .

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2021, 5 (05)

[3] Cos of long-term complications of deep venous thrombosis of the lower extremities: An analysis of a defined patient population in Sweden [J].

Bergqvist, D ;

Jendteg, S ;

Johansen, L ;

Persson, U ;

Odegaard, K .

ANNALS OF INTERNAL MEDICINE, 1997, 126 (06) :454-457

[4] Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis [J].

Brandjes, DPM ;

Buller, HR ;

Heijboer, H ;

Huisman, MV ;

deRijk, M ;

Jagt, H ;

tenCate, JW .

LANCET, 1997, 349 (9054) :759-762

[5] VALIDATING THE SF-36 HEALTH SURVEY QUESTIONNAIRE - NEW OUTCOME MEASURE FOR PRIMARY CARE [J].

BRAZIER, JE ;

HARPER, R ;

JONES, NMB ;

OCATHAIN, A ;

THOMAS, KJ ;

USHERWOOD, T ;

WESTLAKE, L .

BMJ-BRITISH MEDICAL JOURNAL, 1992, 305 (6846) :160-164

[6] Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism [J].

Bueller, Harry R. ;

Decousus, Herve ;

Grosso, Michael A. ;

Mercuri, Michele ;

Middeldorp, Saskia ;

Prins, Martin H. ;

Raskob, Gary E. ;

Schellong, Sebastian M. ;

Schwocho, Lee ;

Segers, Annelise ;

Shi, Minggao ;

Verhamme, Peter ;

Wells, Phil .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (15) :1406-1415

[7] Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis A post-hoc analysis [J].

Cheung, Y. Whitney ;

Middeldorp, Saskia ;

Prins, Martin H. ;

Pap, Akos F. ;

Lensing, Anthonie W. A. ;

ten Cate-Hoek, Arina J. ;

Villalta, Sabina ;

Milan, Marta ;

Beyer-Westendorf, Jan ;

Verhamme, Peter ;

Bauersachs, Rupert M. ;

Prandoni, Paolo .

THROMBOSIS AND HAEMOSTASIS, 2016, 116 (04) :733-738

[8] Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study [J].

Chitsike, R. S. ;

Rodger, M. A. ;

Kovacs, M. J. ;

Betancourt, M. T. ;

Wells, P. S. ;

Anderson, D. R. ;

Chagnon, I. ;

Le Gal, G. ;

Solymoss, S. ;

Crowther, M. A. ;

Perrier, A. ;

White, R. H. ;

Vickars, L. M. ;

Ramsay, T. ;

Kahn, S. R. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (10) :2039-2044

[9] Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study [J].

Cohen, Alexander T. ;

Ay, Cihan ;

Hainaut, Philippe ;

Decousus, Herve ;

Hoffmann, Ulrich ;

Gaine, Sean ;

Coppens, Michiel ;

da Silva, Pedro Marques ;

Jimenez Castro, David ;

Amann-Vesti, Beatrice ;

Brueggenjuergen, Bernd ;

Levy, Pierre ;

Lopez Bastida, Julio ;

Vicaut, Eric ;

Laeis, Petra ;

Fronk, Eva-Maria ;

Zierhut, Wolfgang ;

Malzer, Thomas ;

Bramlage, Peter ;

Agnelli, Giancarlo .

THROMBOSIS JOURNAL, 2018, 16

[10] Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism [J].

Coleman, Craig I. ;

Beyer-Westendorf, Jan ;

Bunz, Thomas J. ;

Mahan, Charles E. ;

Spyropoulos, Alex C. .

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2018, 24 (04) :575-582

← 1 2 3 4 5 →